Literature DB >> 9032045

Inhaled nitric oxide and persistent pulmonary hypertension of the newborn. The Inhaled Nitric Oxide Study Group.

J D Roberts1, J R Fineman, F C Morin, P W Shaul, S Rimar, M D Schreiber, R A Polin, M S Zwass, M M Zayek, I Gross, M A Heymann, W M Zapol.   

Abstract

BACKGROUND: Persistent pulmonary hypertension of the newborn causes systemic arterial hypoxemia because of increased pulmonary vascular resistance and right-to-left shunting of deoxygenated blood. Inhaled nitric oxide decreases pulmonary vascular resistance in newborns. We studied whether inhaled nitric oxide decreases severe hypoxemia in infants with persistent pulmonary hypertension.
METHODS: In a prospective, multicenter study, 58 full-term infants with severe hypoxemia and persistent pulmonary hypertension were randomly assigned to breathe either a control gas (nitrogen) or nitric oxide (80 parts per million), mixed with oxygen from a ventilator. If oxygenation increased after 20 minutes and systemic blood pressure did not decrease, the treatment was considered successful and was continued at lower concentrations. Otherwise, it was discontinued and alternative therapies, including extracorporeal membrane oxygenation, were used.
RESULTS: Inhaled nitric oxide successfully doubled systemic oxygenation in 16 of 30 infants (53 percent), whereas conventional therapy without inhaled nitric oxide increased oxygenation in only 2 of 28 infants (7 percent). Long-term therapy with inhaled nitric oxide sustained systemic oxygenation in 75 percent of the infants who had initial improvement. Extracorporeal membrane oxygenation was required in 71 percent of the control group and 40 percent of the nitric oxide group (P=0.02). The number of deaths was similar in the two groups. Inhaled nitric oxide did not cause systemic hypotension or increase methemoglobin levels.
CONCLUSIONS: Inhaled nitric oxide improves systemic oxygenation in infants with persistent pulmonary hypertension and may reduce the need for more invasive treatments.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9032045     DOI: 10.1056/NEJM199702273360902

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  138 in total

Review 1.  Misuse of correlation and regression in three medical journals.

Authors:  A M Porter
Journal:  J R Soc Med       Date:  1999-03       Impact factor: 5.344

2.  Recent advances in neonatology.

Authors:  J M Rennie; S A Bokhari
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1999-07       Impact factor: 5.747

3.  A randomised control study of partial liquid ventilation after airway lavage with exogenous surfactant in a meconium aspiration syndrome animal model.

Authors:  T Nakamura; S Matsuzawa; M Sugiura; M Tamura
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2000-03       Impact factor: 5.747

Review 4.  Response to inhaled nitric oxide in premature and term neonates.

Authors:  T Hoehn; M F Krause
Journal:  Drugs       Date:  2001       Impact factor: 9.546

5.  Inhaled nitric oxide for hypoxemic respiratory failure: passing bad gas?

Authors:  N D Ferguson; J T Granton
Journal:  CMAJ       Date:  2000-01-11       Impact factor: 8.262

Review 6.  Inhaled nitric oxide treatment for preterm infants with hypoxic respiratory failure.

Authors:  R L Smyth
Journal:  Thorax       Date:  2000-08       Impact factor: 9.139

7.  Cerebral blood flow during treatment for pulmonary hypertension.

Authors:  S Kusuda; N Shishida; N Miyagi; M Hirabayashi; T J Kim
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1999-01       Impact factor: 5.747

Review 8.  Sildenafil for pulmonary hypertension in neonates.

Authors:  Lauren E Kelly; Arne Ohlsson; Prakeshkumar S Shah
Journal:  Cochrane Database Syst Rev       Date:  2017-08-04

9.  Hyperoxia increases phosphodiesterase 5 expression and activity in ovine fetal pulmonary artery smooth muscle cells.

Authors:  Kathryn N Farrow; Beezly S Groh; Paul T Schumacker; Satyan Lakshminrusimha; Lyubov Czech; Sylvia F Gugino; James A Russell; Robin H Steinhorn
Journal:  Circ Res       Date:  2007-11-08       Impact factor: 17.367

10.  Update on PPHN: mechanisms and treatment.

Authors:  Jayasree Nair; Satyan Lakshminrusimha
Journal:  Semin Perinatol       Date:  2014-03       Impact factor: 3.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.